Canada markets open in 7 hours 52 minutes

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
1.98000.0000 (0.00%)
At close: 03:49PM EDT

NervGen Pharma Corp.

2955 Virtual Way
Suite 480
Vancouver, BC V5M 4X6
778 731 1711

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. William Joseph Radvak BAScExec. Chairman97.5kN/A1963
Mr. Paul Anthony Brennan B.Sc., M.Sc.Pres, CEO & Director469.25kN/AN/A
Mr. William J. Adams C.A., CPA, CA, CPACFO & Corp. Sec.378.55kN/A1962
Dr. Daniel D. Mikol M.D., Ph.D.Chief Medical Officer431.24kN/AN/A
Mr. Brian McAlisterCo-Founder & AdvisorN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.

Corporate Governance

NervGen Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.